UC San Diego and Allele together in ARPA-H research project

Introduction

Allele Biotechnology Company, known for its regenerative medicine and modern cell therapy, entered the competitive healthcare sector in 1999. The company is a face of Contract Development and Manufacturing Organisation (CDMO) mainly for cGMP induced pluripotent stem cells and relevant technologies. The company offers clinically proven iPSCs and suitable services to discover patient-centric therapies.

The San Diego-based University of California is a huge and promising public research university system with ten campuses delivering the best of knowledge to future healthcare enthusiast and supporting healthcare companies with their academic potential. The university creates Nobel laureates and encourages innovations that contribute largely to the social mobility, scientific enhancement and smart growth globally.

Announcement

Allele Biotechnology and Pharmaceuticals, Inc. have joined the University of California (UC) for a research project worth $25.8 million. This project is funded and backed by the Advanced Research Projects Agency for Health (ARPA-H). The main focus and purpose of this project is to establish a patient-centric, functional and robust 3D bioprinted liver for the transplantation process. The project is working under its internal, Personalised Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program.

This program intends to equip regenerative medicine ideas and bioprinting technology for 3D printing for organs, which are in heavy demand regardless of immunosuppressive medicines. This acknowledging program is led and hosted by Ryan Spitlet6, PhD, a Program Manager of the ARPA-H.

Project Insight

The project is ready to establish ‘made-to-order’ livers which is emerged from the patient’s own cells. This is a commendable, unique idea that acts as a shield to new solutions against traditional transplantation. This confirmation discards the need for organ donors and a life consuming immunosuppressant medicines. Allele been a part of this project and fulfilling its role for the same will create induced pluripotent stem cells (iPSCs).

The history of this technology is connected by Allele, as Dr Shinya Yamanaka’s innovative technology preferred mRNA reprogramming method at Allele’s GMP facilities, devoted to stem cell-derived therapies. Furthermore, the joint liver regeneration team is directed by a professor in the Aiiso Yufeng Li Family Department of Chemical and Nano Engineering at the UC San Diego Jacobs School of Engineering and a well-recognised 3D bioprinting expert, Shaochen Chen, PhD.

This project has brought all the specialists under one roof to meet the space of artificial intelligence, surgery, liver biology and imaging effectively and deliver on-demand delivery of functional liver tissue for transplantation.